Health & Fitness
Health and Fitness
Health and Fitness
Wed, December 15, 2010
Tue, December 14, 2010
New Results Reveal Extensive Competitive Advantages of VitroGrowa" Stem Cell Culture Media
GOLDEN, Colo.--([ BUSINESS WIRE ])--Vitro Diagnostics, Inc. (OTCBB: VODG) (OTCQB: VODG), dba Vitro Biopharma, announced completion of studies comparing its mesenchymal stem cell culture media, VitroGrowa", to major competitors showing distinct performance improvements over competing products. These new results showed that VitroGrowa" consistently improved mesenchymal stem cell growth, quality, potency and cellular recovery over leading competitors including comparable products sold by InVitrogen, Lonza and Stem Cell Technologies. Furthermore, VitroGrowa" also exhibits real-time stability that exceeds 1 year while competitors published recommended usage periods are 2 weeks to 4 weeks, thus resulting in substantial cost savings and expanded usage opportunities to VitroGrowa" customers.
"Tools for Stem Cell and Drug Developmenta""
Mesenchymal stem cells (MSCs) are adult stem cells present in various tissues including bone marrow, umbilical cord, and fat deposits. MSCs exhibit multipotent differentiation capacity meaning that they have limited ability to differentiate into different cell types while embryonic or induced-pluripotent stem cells can differentiate into any cell of the body. However, MSCs are readily available and initial studies indicate potential clinical benefit in the treatment of orthopedic, autoimmune, cardiovascular, renal and possibly other diseases. Also, based on the number of publications, funded grants and patent applications in the past three years, MSCs are the fastest growing area of stem cell research (BioInformant). The Companya™s highly competitive VitroGrowa" mesenchymal stem cell media thus targets a vital and expanding market within stem cell research. The total market for cell culture media in biotechnology is estimated to be $1.2 billion in 2015 (Bharat). The Company intends to utilize the new studies reported here to optimize its penetration of the mesenchymal stem cell media market through its existing and new stem cell media products now being developed.
Dr. Ivan Rich, Ph.D., CEO of HemoGenix®, Inc., an alliance partner of Vitroa™s, said, aI am very pleased with the expanded competitive advantage of the VitroGrowa" MSC media. This will enable expanded testing at improved sensitivity levels using our Lumenesca" and LumiSTEMa" assay platforms that now include VitroGrowa" media. These new assay platforms offer expanded application of our pioneering HALO® analysis platform for stem cells and will enhance our ability to provide high performance assays to support discovery of expanded research and clinical applications of mesenchymal, embryonic and induced-pluripotent stem cells.a
Dr. Jim Musick, Ph.D., Vitroa™s President and CEO and the inventor of the VitroGrowa" Brand of stem cell media, said, aWe are pleased to report the latest findings of our ongoing studies comparing VitroGrowa" MSC media to our competitora™s products. We are especially pleased that our media outperforms our competitors at both reduced oxygen levels and the oxygen levels of air (~ 20%). While the former more accurately reflects the in-vivo environment, many researchers perform initial studies at ambient oxygen levels, where our media results in substantial increase in MSC growth rate compared to media provided by our competitors. Our media also supports growth of MSCs from human, mouse and rat species thus expanding its application to stem cell research. We are preparing a white paper describing these results in much greater detail.a
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc., dba Vitro Biopharma (OTCBB: VODG) ([ http://www.vitrobiopharma.com ]), owns U.S. patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitroa™s mission is aHarnessing the Power of Cellsa"a for the advancement of regenerative medicine to its full potential. Vitro also owns pending U.S. patents for stem cell therapy of cancer, generation of pluripotent stem cells and is continuously developing patentable cell lines and technologies. Vitro operates within a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells aTools for Stem Cell and Drug Developmenta"a, including human mesenchymal stem cells and derivatives, optimized media for sustained self-renewal, lineage-specific differentiation and products supporting induced pluripotent stem cell and cancer research. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute Lumenesca" and LumiSTEMa" assays for quality and potency determination of MSCs, ESC and iPSCs.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as aintends,a aanticipates,a abelieves,a aexpectsa and ahopesa and include, without limitation, statements regarding the Companya™s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Companya™s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Companya™s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
